Lexicon up 4% on positive early-stage data on neuropathic pain candidate LX9211

• Lexicon Pharmaceuticals (LXRX +4%) is up on below-average volume on the heels of positive results from a Phase 1 multiple ascending-dose clinical trial evaluating neuropathic pain candidate LX9211 in healthy volunteers.
• LX9211 demonstrated a favorable safety profile and pharmacokinetic activity supportive of once-daily dosing. The most common adverse events were headache and dizziness.
• Small molecule LX9211 inhibits an enzyme called adaptor-associated protein kinase 1 (AAK1). The company acquired exclusive rights from development partner Bristol-Myers Squibb two years ago.
• Development is ongoing.